28,781 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Acquired by Tejara Capital Ltd

Tejara Capital Ltd bought a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 28,781 shares of the specialty pharmaceutical company's stock, valued at approximately $825,000. Tejara Capital Ltd owned 0.09% of Collegium Pharmaceutical as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also made changes to their positions in COLL. TD Private Client Wealth LLC boosted its stake in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after buying an additional 483 shares during the period. KBC Group NV boosted its stake in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after buying an additional 982 shares during the period. Nisa Investment Advisors LLC boosted its stake in shares of Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after buying an additional 316 shares during the period. Virtus Fund Advisers LLC acquired a new stake in shares of Collegium Pharmaceutical during the third quarter worth about $72,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Collegium Pharmaceutical by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after buying an additional 642 shares during the period.

Remove Ads

Collegium Pharmaceutical Stock Performance

NASDAQ COLL traded up $0.12 during trading hours on Friday, hitting $30.05. 2,287,750 shares of the stock were exchanged, compared to its average volume of 417,801. Collegium Pharmaceutical, Inc. has a 12-month low of $27.28 and a 12-month high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company has a market cap of $946.15 million, a price-to-earnings ratio of 12.95 and a beta of 0.99. The stock has a 50-day moving average of $30.69 and a 200 day moving average of $32.71.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $181.95 million during the quarter, compared to analysts' expectations of $179.68 million. As a group, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 977 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $29,310.00. Following the completion of the transaction, the chief financial officer now directly owns 164,269 shares of the company's stock, valued at $4,928,070. This trade represents a 0.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now directly owns 154,204 shares of the company's stock, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 109,193 shares of company stock valued at $3,243,594. Corporate insiders own 3.98% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on COLL shares. Piper Sandler decreased their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research note on Tuesday, February 4th. HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target for the company in a report on Friday, January 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical has an average rating of "Moderate Buy" and an average target price of $43.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.